BIOMAT Database Logo BIOMAT Database Logo

Beneficial effect on bone density in male osteoporosis of postmenopausal osteoporosis treatment (fluoride, etidronate, and calcitriol) 1998

M Laroche, and V Andrieu, and A Constantin, and B Mazières

UI MeSH Term Description Entries
D008159 Lumbar Vertebrae VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE. Vertebrae, Lumbar
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002119 Calcium Carbonate Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement. Aragonite,Calcite,Chalk,Limestone,Marble,Milk of Calcium,Vaterite,Calcium Milk,Carbonate, Calcium
D002979 Climacteric Physiologic period, characterized by endocrine, somatic, and psychic changes with the termination of ovarian function in the female. It may also accompany the normal diminution of sexual activity in the male. Change of Life,Climacterics,Life Change,Life Changes
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005272 Femur Neck The constricted portion of the thigh bone between the femur head and the trochanters. Femoral Neck,Neck, Femoral,Neck, Femur
D005459 Fluorides Inorganic salts of hydrofluoric acid, HF, in which the fluorine atom is in the -1 oxidation state. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Sodium and stannous salts are commonly used in dentifrices. Fluoride

Related Publications

M Laroche, and V Andrieu, and A Constantin, and B Mazières
Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
July 1997, Calcified tissue international,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
[Treatment of postmenopausal osteoporosis with etidronate].
March 1999, Minerva medica,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Treatment of postmenopausal osteoporosis with etidronate.
October 1993, The Annals of pharmacotherapy,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
June 1998, Annals of the rheumatic diseases,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
July 1990, The New England journal of medicine,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Intermittent cyclic etidronate treatment of postmenopausal osteoporosis.
September 1995, The American journal of medicine,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Effect of fluoride on postmenopausal osteoporosis.
August 1990, The New England journal of medicine,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women.
June 2002, American journal of physical medicine & rehabilitation,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria.
January 1998, Clinical and experimental rheumatology,
M Laroche, and V Andrieu, and A Constantin, and B Mazières
Etidronate for postmenopausal osteoporosis.
December 1990, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!